

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G.A. Demopulos et al. Attorney Docket No.: OMER-1-17356
Application No.: 09/839,633 Group Art Unit: 1614
Filed: April 20, 2001 Examiner: Jarvis, W.
Title: IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN
AND INFLAMMATION

TRANSMITTAL LETTER

Seattle, Washington 98101

February 22, 2002

TO THE COMMISSIONER FOR PATENTS:

A. Information Disclosure Statement Transmittal

Transmitted herewith is an information disclosure statement, a citation of information, and 45 references in the above-identified application.

Respectfully Submitted,

OMEROS MEDICAL SYSTEMS, INC.



Marcia S. Kelbon
Vice President, Patent and General Counsel
Registration No. 34,358
Direct Dial No. 206.676.5020

I hereby certify that this correspondence is being hand delivered to the Commissioner for Patents, Washington, D.C. 20231, attention Examiner William Jarvis, Group Art Unit 1600 on the below date.

Date: 2/22/02

Person completing Delivery: 

jdg

OMEROS MEDICAL SYSTEMS, INC.
1420 Fifth Avenue
Suite 2675
Seattle, Washington 98101
206.623.4688

RECEIVED
FEB 26 2002
TECH CENTER 1600/2300

RECEIVED
TECH CENTER 1600/2300
02 FEB 22 PM 1:07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G.A. Demopulos et al. Attorney Docket No: OMER-1-17356
Application No.: 09/839,633 Group Art Unit: 1614
Filed: April 20, 2001 Examiner: W. Jarvis
Title: IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN
AND INFLAMMATION

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

February 22, 2002

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. X Copies of the references listed as U13, U25, U136, U158, U167 - U209, U274 - U289, F15, F29 - F95, O157, and O244 - O849 are submitted herewith. Copies of the remaining listed patents, publications, and other information were previously cited by or submitted to the Patent and Trademark Office in prior Application No.s 09/072,913, filed May 4, 1998 and 08/670,699 filed June 26, 1996, and relied upon for an earlier filing date under 35 U.S.C. § 120. It is noted for the Examiner's convenience that the disclosure of each of the cited US Patents to Demopulos et al. is identical, and are cited because of the differing claims.

/

/

/

/

/

/

/

OMEROS MEDICAL SYSTEMS, INC.
1420 Fifth Avenue
Suite 2675
Seattle, Washington 98101
206.623.4688/98101
206.682.8100

RECEIVED
COMM CENTER 1600/2900
02 FEB 22 PM 1:07

2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.

Respectfully submitted,

OMEROS MEDICAL SYSTEMS, INC.



Marcia S. Kelbon
Vice President, Patent and General Counsel
Registration No. 34,358
Direct Dial No. 206.676.5020

I hereby certify that this correspondence is being hand delivered to the Commissioner for Patents, Washington, D.C. 20231, attention Examiner William Jarvis, Group Art Unit 1600 on the below date.

Date: 2/22/02

Person completing Delivery: 

MSK:jdg

OMEROS MEDICAL SYSTEMS, INC.
1420 Fifth Avenue
Suite 2675
Seattle, Washington 98101
206.623.4688

#6

**INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL
TO THE PROSECUTION OF THE SUBJECT APPLICATION**

Applicants: G.A. Demopoulos et al. Attorney Docket No: OMER-1-17356
Serial No: 09/839,633 Group Art Unit: 1614
Filed: April 20, 2001 Examiner: W. Jarvis
Title: IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND
INFLAMMATION

RECEIVED
FBI CENTER 1500/2900
02 FEB 22 PM 7:07

U.S. PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Date	Name
_____	U1	4,504,493	03/12/1985	Marshall et al.
_____	U5	5,051,443	09/24/1991	Neufeld et al.
_____	U6	5,272,139	12/21/1993	Cary
_____	U11	4,872,865	10/10/1989	Bloebaum et al.
_____	U13	4,971,955	11/1990	Soll et al.
_____	U14	4,938,970	07/1990	Hustead et al.
_____	U16	5,304,724	04/19/1999	Newton, W.
_____	U19	5,411,743	05/02/1995	Moore et al.
_____	U20	5,350,761	09/27/1994	Van Duzer et al.
_____	U24	5,288,725	02/22/1994	Witherup et al.
_____	U25	4,640,912	02/03/1987	Hausman, M.
_____	U28	5,536,241	07/16/1996	Zapol, W.
_____	U29	5,512,055	04/30/1996	Domb et al.
_____	U44	4,490,379	12/25/1984	Podos et al.
_____	U45	4,525,359	06/25/1985	Greenway, III et al.
_____	U56	4,880,791	11/14/1989	Weithmann et al.
_____	U61	5,502,080	05/26/1996	Hitzig
_____	U62	5,618,563	04/08/1997	Berde et al.
_____	U63	5,658,955	08/19/1997	Hitzig
_____	U70	5,744,482	04/28/1998	Cohen et al.
_____	U71	5,468,505	11/21/1995	Hubbell et al.

_____	U79	4,659,714	04/21/1987	Watt-Smith
_____	U136	5,605,690	02/25/1997	Jacobs et al.
_____	U158	5,616,688	04/1997	Cerami et al.
_____	U164	5,800,385	09/01/1998	Demopulos et al.
_____	U165	5,820,583	10/13/1998	Demopulos et al.
_____	U167	5,767,064	06/16/1998	Sims et al.
_____	U188	5,319,071	06/07/1994	Dower et al.
_____	U189	5,726,148	03/10/1998	Katoh et al.
_____	U190	5,817,306	10/06/1998	Haskill et al.
_____	U191	5,447,851	09/05/1995	Beutler et al.
_____	U209	5,942,241	8/24/1999	Chasin et al.
_____	U272	5,858,017	01/12/1999	Demopulos et al.
_____	U273	5,860,950	01/19/1999	Demopulos et al.
_____	U274	6,210,394	04/03/2001	Demopulos et al.
_____	U275	6,242,447 B1	06/05/2001	Demopulos et al.
_____	U276	6,254,585 B1	07/03/2001	Demopulos et al.
_____	U277	6,261,279 B1	07/17/2001	Demopulos et al.
_____	U278	6,056,715	05/02/2000	Demopulos et al.
_____	U280	5,610,184	3/11/1997	Shahinian, Jr.
_____	U282	5,480,901	1/2/1996	Baker et al.
_____	U284	6,306,820	10/23/2001	Bendele et al.
_____	U285	5,180,812	01/19/1993	Dower et al.
_____	U286	5,766,585	06/16/1998	Evans et al.
_____	U287	5,767,065	06/16/1998	Mosley et al.
_____	U288	5,449,756	09/12/1995	Taniguchi et al.
_____	U289	5,578,707	11/26/1996	Norick et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Publication Date	Country	Translation Provided	
					Yes	No
_____	F1	WO 95/16435	06/22/1995	PCT	X	
_____	F2	EP 0,364,266 A2	04/18/1990	European	X	
_____	F7	WO 92/04008	03/19/1992	PCT	X	
_____	F8	EP 0,351,755	01/24/1990	European	X	
_____	F9	WO 95/27482	10/19/1995	PCT	X	
_____	F10	WO 91/04058	04/04/1991	PCT	X	
_____	F15	WO 94/06476	03/31/1994	PCT	X	
_____	F16	WO 96/29074	09/26/1996	European	X	
_____	F29	WO 96/26738	09/06/1996	PCT	X	
_____	F61	WO 95/25795	09/28/1995	PCT	X	
_____	F62	WO 96/17869	06/13/1996	PCT	X	
_____	F63	EP 0,623,674 A1	11/09/1994	European	X	
_____	F82	WO 97/24459	07/10/1997	PCT	X	
_____	F83	EP 0,715,855 A2	06/12/1996	European	X	
_____	F84	EP 0,710,479 B1	01/07/1999	European	X	
_____	F85	WO 96/34599	11/07/1996	PCT	X	
_____	F86	WO 98/24477 A1	06/11/1998	PCT	X	
_____	F87	WO 01/87328 A2	11/22/2001	PCT	X	
_____	F88	WO 00/62790	10/26/2000	PCT	X	
_____	F95	WO 00/36108	06/22/2000	PCT	X	

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	ID	Document Information
_____	O01	Thulesius, O., et al., "Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications," <i>J. Cardiovasc. Pharmacol.</i> 9 :728-733 (1987).
_____	O02	Hedner, T., et al., "Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension," <i>Am. J. Hypertens.</i> 1 :317S-323S (1988).
_____	O03	Hof, R.P., et al., "Antiarrhythmic and hemodynamic effects of tropisetron in anesthetized rabbits," <i>J. Cardiovasc. Pharmacol.</i> 22 :499-505 (1993).

- _____ O05 Naesh, O., et al., "Platelet activation in mental stress," *Clin. Physiol.* **13**:299-307 (1993).
- _____ O06 Evans, R.G., et al., "Effects of 5-HT-receptor and alpha 2-androceptor ligands on the haemodynamic response to acute central hypovolemia in conscious rabbits," *Br. J. Pharmacol.* **109**:37-47 (1993).
- _____ O07 Van Hemelrijck, J., et al., "Blood pressure management during aortic surgery: urapidil compared to isosorbide dinitrate," *J. Cardiothorac. Vasc. Anesth.* **7**:273-278 (1993).
- _____ O08 Evans, R.G., et al., "A CNS serotonergic mechanism in acute central hypovolemia in conscious rabbits?" *J. Cardiovasc. Pharmacol.* **19**:1009-1017 (1992).
- _____ O10 Vyssoulis, G.P., et al., "Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives," *Cardiovasc. Drugs Ther.* **4**:81-84 (1990).
- _____ O11 Sigal, S.L., et al., "Effects of Serotonin-Receptor Blockade on Angioplasty-Induced Vasospasm in an Atherosclerotic Rabbit Model," *Arterioscler. Thrombosis* **11**:770-783 (1991).
- _____ O12 Kalsner, S., et al., "Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: a mechanism for coronary spasm," *Science* **223**:1435-1437 (1984).
- _____ O13 Willerson, J.T., et al., "Specific Platelet mediators and unstable coronary artery lesions," *Circulation* **80**:198-205 (1989).
- _____ O14 Saxena, P.R., et al., "Cardiovascular effects on serotonin agonists and antagonists," *J. Cardiovasc. Pharmacol.* **15**:S17-S34 (1990).
- _____ O16 Ashton, J.H., et al., "Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries," *Circulation* **73**:572-578 (1986).
- _____ O17 Douglas, W.W. "Histamine and 5-hydroxytryptamine (serotonin) and their antagonists," In: *The Pharmacological Basis of Therapeutics* 605-638 (1985).
- _____ O20 Kessler, W., et al., "Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P," *Exp. Brain Res.* **91**:467-476 (1992).
- _____ O22 Lang, E., et al., "Chemosensitivity of fine afferents from rat skin in vitro," *J. Neurophysiol.* **63**:887-901 (1990).

- _____ O23 Levine, J.D., et al., "Desipramine enhances opiate postoperative analgesia," *Pain* **27**:45-49 (1986).
- _____ O25 Richardson, B.P., et al., "Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs," *Nature* **316**:126-131 (1985).
- _____ O26 Ringkamp, M., et al., "Activated human platelets in plasma excite nociceptors in rat skin, in vitro," *Neurosci. Lett.* **170**:103-106 (1994).
- _____ O32 Buzzi, M.G., et al., "The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater," *Br. J. Pharmacol.* **99**:202-206 (1990).
- _____ O33 Buzzi, M.G., et al., "5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation," *Brain Res.* **583**:137-149 (1992).
- _____ O34 Zochodne, D.W., et al., "Sumatriptan blocks neurogenic inflammation in the peripheral nerve trunk," *Neurology* **44**:161-163 (1994).
- _____ O37 Schwartz, M.M., et al., "Vascular leakage in the kidney and lower urinary tract: effects of histamine, serotonin and bradykinin," *Proc. Soc. Exp. Biol. Med.* **140**:535-539 (1972).
- _____ O38 Holliman, C.J., et al., "The effect of ketanserin, a specific serotonin antagonist, on burn shock hemodynamic parameters in a porcine burn model," *J. Trauma* **23**:867-871 (1983).
- _____ O39 Serruys, P.W., et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty; a multicenter randomized double-blind placebo-controlled trial," *Circulation* **88**:1588-1601 (1993).
- _____ O40 Cohen, B.M., et al., "Intracoronary cocktail infusion during rotational ablation: safety and efficacy," *Transcatheter Cardiovascular Therapeutics* (1995).
- _____ O43 Berkenboom, G., et al., "Atherosclerosis and responses of human isolated coronary arteries to endothelium-dependent and -independent vasodilators," *J. Cardiovasc. Pharmacol.* **14**:S35-S39 (1989).
- _____ O44 Kaumann, A.J., et al., "Variable participation of 2HT1-like receptors and 5-HT1 receptors in serotonin-induced contraction of human isolated coronary arteries," *Circulation* **90**:1141-1153 (1994).

- _____ O45 Quast, U., et al., "Cellular Pharmacology of Potassium Channel Openers in Vascular Smooth Muscle," *Cardiovascular Research* **28**:805-810 (1994).
- _____ O86 Golino, P., et al., "Failure of nitroglycerine and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for thromboxane A₂ and serotonin as mediators of coronary artery vasoconstriction in vivo," *J. Am. Coll. Cardiol.* **15**:718-726 (1990).
- _____ O89 DeCaterina, R., et al., "A Double-blind, Placebo-controlled Study of Ketanserin in Patients with Prinzmetal's Angina," *Circulation* **69**:889-894 (1984).
- _____ O90 Golino, P., et al., "Divergent Effects of Serotonin on Coronary-Artery Dimensions and Blood Flow in Patients with Coronary Artherosclerosis and Control Patients," *New Engl. J. Med.* **324**:641-648 (1991).
- _____ O91 Golino, P., et al., "Local Effect of Serotonin Released During Coronary Angioplasty," *New Engl. J. Med.* **330**:523-528 (1994).
- _____ O93 Ashton, J.H., et al., "Serotonin S₂ and Thromboxane A₂-Prostaglandin H₂ Receptor Blockade Provide Protection Against Epinephrine-Induced Cyclic Flow Variations in Severely Narrowed Canine Coronary Arteries," *J. Am. Coll. Cardiol.* **13**:755-763 (1989).
- _____ O94 Yao, S., et al., "Combined ADP and Thromboxane A₂ Antagonism Prevents Cyclic Flow Variations in Stenosed and Endothelium-Injured Arteries in Nonhuman Primates," *Circulation* **88**:2888-2893 (1993).
- _____ O116 Cohen, B.M., et al., "Cocktail attenuation of rotational ablation flow effects (CARAFE) study: pilot," *Cathet. Cardiovasc. Diagn. Suppl.* **3**:69-72 (1996).
- _____ O133 Sosnowski, M., et al., "Spinal Administration of Receptor-Selective Drugs as Analgesics: New Horizons," *J. Pain Symptom Manag.* **5**:204-213 (1990).
- _____ O157 Thomas, et al., "The Direct Perfusion of Surgical Wounds with Local Anaesthetic Solution: An Approach to Postoperative Pain?," *Annal R Coll Surg* **65**:226-229 (1983).
- _____ O160 Kuga, T., et al., "Inhibitory Effects of Aspirin on Coronary Hyperreactivity to Autacoids After Arterial Balloon Injury in Minature Pigs," *J. Cardiovasc. Pharmacol.* **25**:273-281 (1995).

- _____ O175 Reifart, et al., "Randomized Comparison of Angioplasty of Complex Coronary Lesions at a Single Center," *Circulation* **96**:91-98 (1997).
- _____ O178 Willerson, J.T., et al., "Pretreatment with Antagonists to Thromboxane A2, Serotonin and ADP Reduces Neointimal Proliferation in Canine Coronary Arteries after Endothelial Injury," *J. Am. Coll. Cardiol.* **Incomplete Data**:906-32(1994).
- _____ O180 Knorr, A.M. "Why is Nisoldipine a Specific Agent in Ischemic Left Ventricular Dysfunction?" *Am. J. Cardiol.* **75**:36E-40E (1995).
- _____ O181 Pierce, P.A., et al., "Dual Effect of the Serotonin Agonist, Sumatriptan, on Peripheral Neurogenic Inflammation," *Reg. Anesth.* **21**:219-225 (1996).
- _____ O183 Herrman et al., "Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty," *Drugs* **46**:18-52 (1993).
- _____ O184 Vahanian et al., "Role of Calcium Channel Blockers in Reducing Acute Ischemia and Preventing Restenosis in PCTA," *Drugs* **52**:9-15 (1996).
- _____ O185 Narayanan et al., "Recombinant Hirudin: Initial Observations in Reconstructive Microsurgery," *Haemostasis* **21**:168-171 (1991).
- _____ O186 el-Sanadiki, M.N., et al., "Reduction of Intimal Hyperplasia and Enhanced Reactivity of Experimental Vein Bypass Grafts with Verapamil Treatment," *Ann. Surg.* **212**:87-96 (1990).
- _____ O195 Blackham et al., "FPL 62064 a Topically Active 5-Lipoxygenase/Cyclooxygenase Inhibitor," *Agents and Actions* **30**:432-442.
- _____ O196 Hirayama et al., "NK₂ Receptors Mediate Tachykinin-Induced Plasma Extravasation in the Rat Knee," *Agents Actions* **40**:171-175 (1994).
- _____ O244 Klein, J.A., "The Tumescence Technique Anesthesia and Modified Liposuction Technique," *Dermatologic Clinics* **8**:425-437 (1990).
- _____ O246 Ostad et al., "Tumescence Anesthesia with a Lidocaine Dose of 55 mg/kg is Safe for Liposuction" *Dermatol Surg* **22**:921-927 (1996).
- _____ O341 Moreland, et al., "Treatment Of Rheumatoid Arthritis With A Recombinant Human Tumor Necrosis Factor Receptor (P75)-Fc Fusion Protein [See Comments]," *N Engl J Med* **337**:141-147 (1997).

- _____ O342 Moreland, et al., "Recombinant Soluble Tumor Necrosis Factor Receptor (P80) Fusion Protein: Toxicity And Dose Finding Trial In Refractory Rheumatoid Arthritis," *J Rheumatol* **23**:1849-1855 (1996).
- _____ O609 Mohler et al., "Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents In Lethal Endotoxemia And Function Simultaneously As Both TNF Carriers And TNF Antagonists," *J Immunol* **151**:1548-1561 (1993).
- _____ O843 Ettehadhi et al., "Elevated Tumour Necrosis Factor-Alpha (TNF-Alpha) Biological Activity In Psoriatic Skin Lesions," *Clin Exp Immuno* **96**:146-151 (1994)
- _____ O848 Jacobi, et al., "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model," *Am J Surg* **174**:359-363 (1997).
- _____ O849 Karczag, et al., "Mouse Peritoneal Cells Activated With a Combination of Indomethacin, Poly I: C and Syncumar Inhibit the Take of Lewis Lung Carcinoma, in Adoptive Transfer Assay," *Acta Microbiologia Hung* **34**:207-214 (1987).

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MSK:jdjg